What interviewers actually evaluate

Regeneron Pharmaceuticals finance interviews test whether candidates understand the financial model of a biopharmaceutical company where collaboration accounting for co-developed products, high sustained R&D investment as a percentage of revenue, and product lifecycle transitions from market growth to biosimilar competition create financial analysis and reporting challenges distinct from both standard industrial company finance and pure royalty or licensing revenue pharmaceutical models. Finance at Regeneron spans collaboration accounting for the Sanofi partnership (where DUPIXENT and LIBTAYO are developed and commercialized under collaboration agreements with Sanofi that require Regeneron to recognize its share of US collaboration profits – the net revenue minus the collaboration expenses – rather than gross product revenue, and where EYLEA collaboration revenue from Bayer for ex-US sales is recognized as royalty and collaboration income based on Bayer's net sales in licensed territories, creating a revenue recognition structure where the line between product sales, collaboration income, and royalty revenue must be correctly identified for each product-market combination), R&D investment management and clinical stage financial governance (where Regeneron invests heavily in its research and development pipeline – with R&D spending often exceeding 40 percent of total revenues – and where finance must support stage-gate investment decisions, track clinical development milestone progress against budget, and evaluate the probability-adjusted value of pipeline assets that may be years from generating commercial revenue but that represent the source of Regeneron's long-term earnings growth), EYLEA revenue projection under biosimilar competition (where EYLEA's net US revenue is declining as biosimilar aflibercept products compete for retina specialist prescribing and payer formulary placement – finance must model the rate of market erosion under different competitive scenarios, project how EYLEA HD's clinical differentiation affects the speed and extent of market share loss, and communicate the EYLEA revenue trajectory to investors who are assessing how much of Regeneron's EYLEA revenue DUPIXENT growth must offset to sustain total revenue growth), and DUPIXENT financial modeling and payer contract economics (where DUPIXENT's US collaboration profit to Regeneron depends on gross-to-net adjustments – the rebates paid to PBMs and health plans for formulary access, the government mandated discounts under Medicaid best price and 340B programs, and the co-pay assistance spending under Regeneron Cares – that determine how much of DUPIXENT's wholesale acquisition cost actually flows through to Regeneron's income statement as collaboration profit). Interviewers evaluate whether candidates understand pharmaceutical collaboration accounting, R&D stage-gate financial governance, biosimilar competition revenue modeling, and gross-to-net revenue adjustment analysis for high-cost biologic medicines.

Start your free Regeneron Pharmaceuticals Finance practice session.

What interviewers actually evaluate

Collaboration Accounting, R&D Investment Governance, and Biosimilar Revenue Impact Analysis

Regeneron finance interviews probe whether candidates understand how biopharmaceutical finance differs from both manufacturing and technology company finance in the collaboration accounting complexity (Regeneron's income statement does not simply show product sales minus cost of goods and operating expenses – for DUPIXENT, Regeneron recognizes its share of US collaboration net profit from the Sanofi collaboration, which means that the revenue line reflects Regeneron's share of the collaboration's US operations after Sanofi's contribution and after collaboration expenses, creating accounting that requires understanding the collaboration agreement's profit-sharing provisions to interpret the income statement correctly, and where changes in Sanofi's commercial investment levels or collaboration expense allocations affect Regeneron's recognized income in ways that are not visible from product sales data alone), the R&D productivity financial challenge (Regeneron's investment thesis is built on the productivity of its VelocImmune platform and the Regeneron Genetics Center generating a flow of potentially first-in-class drug candidates that justify sustained high R&D spending – finance teams who analyze Regeneron must evaluate the R&D investment not just as a cost but as the source of the pipeline that generates future revenue, requiring probability-weighted revenue forecasting, pipeline portfolio value analysis, and stage-gate investment governance that industrial company finance frameworks do not typically encompass), and the EYLEA to DUPIXENT revenue mix transition (Regeneron's financial story has been evolving from EYLEA dominance to DUPIXENT growth offsetting EYLEA biosimilar headwinds – understanding how quickly biosimilar penetration typically erodes a reference biologic's market share, how EYLEA HD's extended dosing data affects the erosion trajectory, and what DUPIXENT growth rate is required for total Regeneron revenue to continue growing despite EYLEA headwinds is the core financial narrative that investors, analysts, and Regeneron's own financial planning team must model correctly).

The Inflation Reduction Act's Medicare drug pricing negotiation provisions create a new financial risk dimension for Regeneron: EYLEA and potentially DUPIXENT may be subject to Medicare price negotiation under IRA provisions that apply to Medicare Part D drugs with high spend and no generic competition, creating uncertainty about future net revenue from these products' Medicare populations that was not present in prior pharmaceutical financial planning.

What gets scored in every session

Specific, sentence-level feedback.

Dimension	What it measures	How to answer
Sanofi collaboration accounting and revenue recognition	Do you understand how Regeneron recognizes revenue from its Sanofi collaboration – how DUPIXENT collaboration profit is calculated, how EYLEA Bayer royalties are recognized differently from US product revenue, and how changes in collaboration terms or Sanofi commercial investment affect Regeneron's recognized income? We flag finance answers that treat all pharmaceutical revenue as straightforward product sales rather than engaging with collaboration accounting structures.	Collaboration profit calculation, royalty vs product revenue distinction, collaboration term impact analysis
R&D investment governance and pipeline valuation	Can you describe how to provide financial governance for a high-R&D biopharmaceutical pipeline – how stage-gate investment decisions are evaluated, what probability-adjusted NPV frameworks apply to pipeline assets, and how to communicate the long-term value creation logic of heavy R&D spending to investors who apply near-term earnings multiples? We score whether your R&D governance approach engages with pharmaceutical pipeline probability and NPV analysis.	Stage-gate investment criteria, probability-adjusted pipeline NPV, R&D investor communication
EYLEA biosimilar revenue impact modeling	Can you model how biosimilar competition affects EYLEA revenue – what market share erosion assumptions are appropriate based on reference biologic experience in the US, how EYLEA HD's differentiation slows or limits erosion in certain patient segments, and how to communicate the EYLEA revenue trajectory alongside DUPIXENT growth to demonstrate total revenue sustainability? We detect finance answers that treat biosimilar competition as binary without modeling the gradual erosion dynamic or the differentiation factors that affect erosion pace.	Biosimilar market share erosion modeling, reference biologic comparables, EYLEA HD differentiation financial value
Gross-to-net analysis for specialty biologic pricing	Do you understand how gross-to-net adjustments work for a high-cost biologic like DUPIXENT – what rebate categories contribute to the gap between WAC and net price, how Medicaid best price and 340B requirements affect gross-to-net, and how payer rebate negotiations affect the net revenue that DUPIXENT collaboration profit calculations begin from? We flag finance answers that use WAC as a proxy for actual net revenue without engaging with the gross-to-net complexity of specialty biologic pricing.	PBM rebate and formulary fee analysis, Medicaid best price impact, gross-to-net trend monitoring

How a session works

Step 1: Choose a Regeneron Pharmaceuticals finance scenario – Sanofi collaboration revenue recognition and profit-sharing accounting, R&D pipeline investment governance and stage-gate financial analysis, EYLEA biosimilar competition revenue impact modeling, or DUPIXENT gross-to-net analysis and specialty biologic pricing economics.

Step 2: The AI interviewer asks realistic Regeneron-style questions: how you would explain to a new financial analyst why Regeneron's income statement for DUPIXENT does not show a revenue line equal to the total US DUPIXENT WAC net sales reported in press coverage – walking through how collaboration profit recognition, gross-to-net adjustments, and collaboration expense offsets transform total US sales into the figure that Regeneron reports as collaboration income, how you would build the 5-year financial model for Regeneron's total revenue given EYLEA's biosimilar headwind and DUPIXENT's growth trajectory – including the key assumptions about biosimilar penetration rate, EYLEA HD's market protection effect, DUPIXENT's annual net revenue growth, and whether DUPIXENT growth is sufficient to offset EYLEA erosion and sustain revenue growth through the projection period, or how you would evaluate a proposed $2 billion increase in annual R&D investment focused on next-generation inflammation biologics given Regeneron's current R&D productivity metrics, probability-adjusted pipeline NPV, and the competitive innovation landscape in Type 2 inflammation where multiple companies are developing IL-4, IL-13, IL-33, and TSLP pathway inhibitors.

Step 3: You respond as you would in the actual interview. The system scores your answer on collaboration accounting, R&D investment governance, biosimilar revenue modeling, and gross-to-net analysis.

Step 4: You get sentence-level feedback on what demonstrated genuine biopharmaceutical finance expertise and what needs stronger collaboration accounting understanding or biosimilar erosion modeling specificity.

Frequently Asked Questions

How does Regeneron recognize revenue from the Sanofi DUPIXENT collaboration?
Under the Regeneron-Sanofi collaboration agreement, Sanofi leads global commercialization of DUPIXENT and bears the majority of commercialization expenses outside the US. In the United States, both companies deploy commercial teams under a co-promotion arrangement, and the US collaboration profits – net US revenues minus collaboration expenses including cost of goods, selling expenses, and R&D costs allocated to DUPIXENT – are shared, with Regeneron retaining approximately 50 percent of US collaboration profits after expenses. Regeneron's income statement reflects this structure by showing Collaboration Revenue rather than Product Sales for DUPIXENT, with the amount representing Regeneron's share of the collaboration's US net income from DUPIXENT. For EYLEA, Regeneron recognized royalties from Bayer on Bayer's net sales of EYLEA in licensed ex-US territories, and recorded US EYLEA net product sales directly – a different structure than the DUPIXENT profit-sharing arrangement that requires careful attention when analyzing Regeneron's revenue composition.

How do R&D stage-gate decisions work at a biopharmaceutical company?
Regeneron invests in drug candidates across multiple therapeutic areas through a staged development process where compounds progress from research and preclinical development through Phase 1, Phase 2, and Phase 3 clinical trials before regulatory submission. At each stage transition, Regeneron makes an investment decision – to continue development, to modify the program, or to discontinue – based on the clinical and translational data generated in prior stages, the competitive landscape in the target indication, and the updated probability-weighted commercial value of the asset. Finance supports these decisions by building NPV models that estimate the asset's value at each stage transition given current probability-of-success estimates and commercial forecasts, and by comparing the incremental investment required for the next stage against the probability-adjusted expected value creation. For collaboration assets like DUPIXENT pipeline indications, Sanofi's perspective on stage-gate decisions is incorporated through the joint development committee that governs shared pipeline assets.

How do biosimilar products typically erode reference biologic market share?
The US biologic market has experienced biosimilar entry for several major reference products, and the pattern of erosion varies significantly based on the product's indication, the payer dynamics governing coverage, and the reference manufacturer's response strategy. In some categories – infliximab biosimilars for immunology, for example – payers aggressively shifted formulary preference to biosimilars and market share erosion of the reference product was rapid and substantial. In other categories, particularly those where the reference manufacturer has strong physician relationships, robust patient support infrastructure, and meaningful clinical differentiation data, erosion has been slower. EYLEA HD's extended dosing data provides a clinical differentiation argument that may slow erosion in retina specialist prescribing patterns among patients who benefit from less frequent in-office visits, while payer formulary decisions for the broader aflibercept market segment may shift toward biosimilar preference more rapidly in cost-managed settings.

What are gross-to-net adjustments and why do they matter for DUPIXENT?
Pharmaceutical gross-to-net adjustments are the discounts, rebates, and fees that reduce a drug's wholesale acquisition cost to the net revenue that the manufacturer actually realizes. For DUPIXENT, major gross-to-net components include: PBM formulary rebates negotiated with large pharmacy benefit managers for formulary access, government program mandatory rebates under Medicaid best price regulations that require manufacturers to provide state Medicaid programs the same or better pricing as the lowest commercial customer price, 340B program discounts for covered entities that qualify for reduced drug pricing, and co-pay assistance spending under Regeneron Cares that the company funds to reduce patient out-of-pocket costs. The aggregate gross-to-net adjustment for specialty biologics like DUPIXENT can be substantial – sometimes 30-50 percent of WAC depending on the mix of channel and payer – making the gross-to-net analysis essential for understanding true net revenue and collaboration profit calculations.

How does the Inflation Reduction Act affect Regeneron's financial planning?
The Inflation Reduction Act of 2022 created a Medicare drug pricing negotiation program under which CMS negotiates prices for certain high-spend Medicare drugs without generic or biosimilar competition. EYLEA was among the first drugs selected for IRA Part B negotiation for drugs administered in physician offices, affecting the Medicare Part B reimbursement for EYLEA in retina specialist practices. For Regeneron's financial planning, IRA negotiated prices represent a downward pressure on net revenue from Medicare Part B patients specifically, which for EYLEA represents a significant portion of total patients given that wet AMD predominantly affects elderly Medicare beneficiaries. Finance must model the IRA impact on Medicare reimbursement, the behavioral response from retina practices and their prescribing decisions if Medicare reimbursement approaches the biosimilar price, and the net effect on EYLEA's total net revenue and contribution to Regeneron's collaboration income over the period that negotiated prices apply.